Royalty Pharma plc (RPRX)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow RPRX in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on RPRX and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
RPRX at a glance
Key statistics
$27.72B
Market capitalization
- Previous close
- $62.25
- Open
- $62.16
- Day range
- $62.06 – $62.81
- Volume
- 1.12M
- Average volume (30 sessions)
- 3.10M
- Shares outstanding
- 445.28M
- Price / earnings
- 34.0
- Earnings per share
- $1.83
- Price / book
- 4.1
- Price / sales
- 10.9
- Dividend yield
- 1.44%
- Beta (1 year, vs SPY)
- 0.24
Where the price sits in its year
52-week range
93% of the range
- Below the 52-week high
- -3.2%
- Above the 52-week low
- +73.5%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $58.17+7.0%
- 50-day average
- $59.43+4.7%
- 200-day average
- $52.25+19.1%
Between the conventional 30 and 70 bands.
+10.0%
1 week
+6.5%
1 month
+6.0%
3 months
+61.1%
Year to date
+68.2%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with RPRX
RPRX on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on RPRX.
See the plans →
Every planScreen names like RPRX
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on RPRX
Put RPRX on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on RPRX
See whether there is an open premium alert on RPRX, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
RPRX headlines
- Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
GlobeNewswire Inc. · Sep 4, 2026
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
GlobeNewswire Inc. · Apr 21, 2026
- Royalty Pharma Declares Second Quarter 2026 Dividend
Benzinga · Apr 17, 2026
- Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
GlobeNewswire Inc. · Mar 2, 2026
- Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
GlobeNewswire Inc. · Jan 11, 2026
- Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
GlobeNewswire Inc. · Jan 11, 2026
- Royalty Pharma Announces Dividend Increase
Benzinga · Jan 9, 2026
- What's Going On With Royalty Pharma Stock Wednesday?
Benzinga · Dec 31, 2025
SEC Form 4, most recent first
Insider filings
Urist Marshall
−4.1K
EVP, Research & Investments · Open-market sale
$235.59K · Oct 5, 2026
Urist Marshall
−4.1K
EVP, Research & Investments · Open-market sale
$238.81K · Sep 28, 2026
Bassler Bonnie L
+642
Director · Grant or award
$37.50K · Sep 30, 2026
Hite Christopher
−3.9K
EVP & Chairman, Partnering · Open-market sale
$231.40K · Sep 22, 2026
Hite Christopher
−96.1K
EVP & Chairman, Partnering · Open-market sale
$5.62M · Sep 22, 2026
Hite Christopher
−100.0K
EVP & Chairman, Partnering · Open-market sale
$6.00M · Aug 18, 2026
Hite Christopher
−16.8K
EVP & Chairman, Partnering · Gift
· Aug 19, 2026
Coyne Terrance P.
−1.8K
EVP & CFO · Open-market sale
$104.80K · Aug 13, 2026
About Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Employees
- 100
- Listed since
- Jun 16, 2020
- Website
- royaltypharma.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.